CC16在慢性阻塞性肺疾病急性加重期血清和痰液中的变化及临床意义

目的 通过测定慢性阻塞性肺疾病急性加重期（AECOPD）、慢性阻塞性肺疾病（COPD）稳定期患者的血清及痰液中Clara细胞分泌蛋白（CC16）的变化,探讨血清及痰液CC16在诊治AECOPD中的临床意义。方法 随机选择我院呼吸内科住院及门诊COPD患者共61例,其中AECOPD患者31例、COPD稳定期患者30例,同时招募吸烟非COPD 30例和不吸烟对照组30例。收集患者及对照组临床资料、血清和痰液标本,采用ELISA法测定血清及痰液CC16、白介素-6（IL-6）、白介素-8（IL-8）、白介素-10（IL-10）、肿瘤坏死因子-α（TNF-α）水平。结果 AECOPD组血清及痰液CC16、IL-10显著低于COPD稳定期组及对照组（P〈0.05）,而IL-6、IL-8、TNF-α显著高于COPD稳定期组及对照组（P〈0.05）。AECOPD组血清及痰液中CC16与IL-6、IL-8、TNF-α水平呈明显的负相关性（P〈0.05）,与IL-10呈明显正相关性（P〈0.05）。结论 CC16可作为AECOPD的参考生物学标志物。

Changes and clinical significance of CC16 in sputum and serum of acute exacerbation of chronic obstructive pulmonary disease

Objective To expore the significance of Clara cell secretory protein（CC16） in serum and sputum in patients of acute exacerbation of chronic obstructive pulmonary disease （AECOPD）. Through measuring the level of CC16 in serum and sputum between the patients with AECOPD, chronic obstructive pulmonary disease（COPD） in stable phrase and healthy controls. Methods A total of 61 patients with COPD were randomly chosed from our respiratory medicine. They included 31 patients with AECOPD and 30 patients with stable COPD. 30 healthy smokers and 30 healthy nonsmokers were recruited as the control group. The clinical data, serum and sputum samples were collected from all the subjects to measure CC16, interleukin-6 （ IL-6 ）, interleukin-8 （ IL-8 ）, interleukin-10 （ IL-10 ） and tumor necrosis factor-or （TNF-α） by ELISA. Results The level of CC16, IL-10 in serum and sputum of patients with AECOPD were significantly lower than the stable COPD and the control group （ P 〈 0.05 ）. However IL-6, IL-8 and TNF-c~ were significantly higher than the stable COPD and the control group （P 〈 0.05 ）. CC16 was negative correlated with IL-6, IL-8 and TNF-α（ P 〈 0.05） and was positive correlated with IL-10 （ P 〈 0. 05 ） in serum and sputum in patients of AECOPD. Conclusions CC16 can be used as biological marker of AECOPD.